MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor…
<!-- Name:DistributionId Value:8752994 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:MNOV
MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase…
<!-- Name:DistributionId Value:8745503 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002…
LA JOLLA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock…
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002…
LA JOLLA, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock…
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral…
LA JOLLA, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock…
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001…
LA JOLLA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock…
MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166…
LA JOLLA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo…
MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a…
LA JOLLA, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo…
MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166…
LA JOLLA, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo…
MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of…
LA JOLLA, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo…